Pharmaceutical stratégies utilizing recombinant human serum albumin

Gene manipulation techniques open up the possibility of making recombinant human serum albumin (rHSA) or mutants with desirable therapeutic properties and for protein fusion products. rHSA can serve as a carrier in synthetic heme protein, thus reversibly carrying oxygen. Myristoylation of insulin re...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 2002-05, Vol.19 (5), p.569-577
Main Authors: TUAN GIAM CHUANG, Victor, KRAGH-HANSEN, Ulrich, OTAGIRI, Masaki
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biological Transport
Biotechnology industry
Blood & organ donations
Blood Substitutes - chemistry
Blood Substitutes - pharmacokinetics
Blood-brain barrier
Blood-Brain Barrier - physiology
Carbon
Drug Carriers
Drug delivery systems
General pharmacology
Genetic Vectors
Glucose
Humans
Insulin - chemistry
Insulin - pharmacokinetics
Medical sciences
Microspheres
Mutation
Pharmaceutical industry
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Plasma
Protein Binding
Proteins
Recombinant Proteins - biosynthesis
Recombinant Proteins - chemistry
Serum Albumin - biosynthesis
Serum Albumin - chemistry
Serum Albumin - genetics
Ultrasonic imaging
Yeast
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gene manipulation techniques open up the possibility of making recombinant human serum albumin (rHSA) or mutants with desirable therapeutic properties and for protein fusion products. rHSA can serve as a carrier in synthetic heme protein, thus reversibly carrying oxygen. Myristoylation of insulin results in a prolonged half-life because of self aggregation and increased albumin binding. Preferential albumin uptake by tumor cells serves as the basis for albumin-anticancer drug conjugate formulation. Furthermore, drug targeting can be achieved by incorporating drugs into albumin microspheres whereas liver targeting can be achieved by conjugating drug with galactosylated or mannosylated albumin. Microspheres and nanoparticles of different sizes can, with or without drugs and/or radioisotopes, be used for drug delivery or diagnostic purposes. In vivo implantation of albumin fusion protein expressing cells encapsulated in HSA-alginate coated beads showed promising results compared to organoids in rats. Chimeric peptide strategy with cationized albumin as the transport can deliver drugs via receptor mediated transcytosis through the blood brain barrier. Gene bearing, albumin microbubbles containing ultrasound contrast agents can non-invasively deliver gene after destruction by ultrasound. Various site-directed mutants of HSA can be tailor made depending on the application required.
ISSN:0724-8741
1573-904X